Ergomed - What’s next after stellar 2020 performance?
Although most of 2020 was challenging for the contract research outsourcing (CRO) sector, for Ergomed it was a transformative growth period due to...
626 Views
Ergomed - Adj EBITDA upgrade despite industry challenges
H120 adjusted EBITDA of £9.1m was the main positive surprise for us in Ergomed’s full interim report released today. We have increased our adjusted...
88 Views
Ergomed - Diversified services offering proves resilient
According to Ergomed’s H120 trading update, the business successfully navigated the COVID-19 pandemic in H120. Underlying revenues in the...
79 Views
Ergomed - AGM update: ‘Revenue growth trend’ maintained
Today Ergomed held its annual general meeting (AGM). As expected, no new financial details were provided, although the executive chairman released...
54 Views
Ergomed - Resilient global pharma services specialist
We are initiating coverage on specialist pharmaceutical services provider Ergomed. We believe it should prove relatively resilient during the...
565 Views